Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LifeTech Scientific Corporation (1302.HK)
Shenzhen, HK
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. The company’s products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, HeartR, and Konar-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; Futhrough endovascular needle systems; delivery systems, such as Fustar steerable and SteerEase introducers; Zoetrack guidewire; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; HearTone implantable cardiac pacing system; and SeQure snare systems, as well as pacemakers. It also involved in the biomedical research and development; properties leasing business; and developing, manufacturing, and trading of medical devices, as well as offers technical, consulting, and technology services. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.49% | -29.36% | -23.15% | +1.22% | -13.54% | +6.41% | +2.47% | -31.12% | -67.64% | +26.72% | +564.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-09 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+5.1% Q4'25: +10.4% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%-35.0% Q4'25: +109.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+20.0% ★ Q4'25: +20.2% (vs Q4'23)
-
EBIT margin Medical - Specialties: +12.6%+14.3% ★ Q4'25: +23.8% (vs Q4'23)
-
ROIC Medical - Specialties: +6.6%+5.1% Q4'25: +18.3% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%+0.5% Q4'25: +2.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.03× ★ Q4'25: 0.01× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
231.04M
est: 202.26M (+14.2%)
|
311.61M
est: 371.18M (-16.0%)
|
352.85M
est: 366.49M (-3.7%)
|
409.13M
est: 495.78M (-17.5%)
|
556.70M
est: 611.80M (-9.0%)
|
668.88M
est: 809.86M (-17.4%)
|
642.30M
est: 872.63M (-26.4%)
|
925.33M
est: 1.21B (-23.3%)
|
1.10B
est: 1.48B (-25.7%)
|
1.27B
est: 1.45B (-12.5%)
|
1.30B
est: 1.47B (-11.5%)
|
1.37B
est: 1.40B (-2.3%)
|
1.52B
1.52B – 1.52B
+8.5% YoY
|
1.70B
1.70B – 1.70B
+11.9% YoY
|
1.93B
1.93B – 1.93B
+13.2% YoY
|
| EBITDA |
48.53M
est: 70.13M (-30.8%)
|
82.34M
est: 128.69M (-36.0%)
|
120.10M
est: 127.07M (-5.5%)
|
211.45M
est: 171.90M (+23.0%)
|
200.03M
est: 212.12M (-5.7%)
|
246.22M
est: 280.79M (-12.3%)
|
314.14M
est: 302.55M (+3.8%)
|
397.59M
est: 418.51M (-5.0%)
|
445.78M
est: 512.00M (-12.9%)
|
253.46M
est: 502.35M (-49.5%)
|
271.87M
est: 429.50M (-36.7%)
|
291.74M
est: 408.79M (-28.6%)
|
443.52M
443.52M – 443.52M
+8.5% YoY
|
496.42M
496.42M – 496.42M
+11.9% YoY
|
561.73M
561.73M – 561.73M
+13.2% YoY
|
| EBIT |
-43.05M
est: 57.62M (-174.7%)
|
39.65M
est: 105.74M (-62.5%)
|
202.99M
est: 104.41M (+94.4%)
|
194.44M
est: 141.24M (+37.7%)
|
167.47M
est: 174.29M (-3.9%)
|
191.03M
est: 230.72M (-17.2%)
|
268.32M
est: 248.60M (+7.9%)
|
335.54M
est: 343.88M (-2.4%)
|
378.68M
est: 420.69M (-10.0%)
|
176.30M
est: 412.76M (-57.3%)
|
208.38M
est: 338.70M (-38.5%)
|
195.41M
est: 322.37M (-39.4%)
|
349.75M
349.75M – 349.75M
+8.5% YoY
|
391.47M
391.47M – 391.47M
+11.9% YoY
|
442.97M
442.97M – 442.97M
+13.2% YoY
|
| Net Income |
-65.67M
|
2.36M
est: 88.25M (-97.3%)
|
145.65M
est: 104.81M (+39.0%)
|
163.47M
est: 133.51M (+22.4%)
|
121.08M
est: 146.78M (-17.5%)
|
129.20M
est: 155.87M (-17.1%)
|
216.09M
est: 157.81M (+36.9%)
|
292.47M
est: 352.09M (-16.9%)
|
325.34M
est: 436.82M (-25.5%)
|
263.24M
est: 350.24M (-24.8%)
|
222.39M
est: 309.16M (-28.1%)
|
147.83M
est: 309.14M (-52.2%)
|
274.94M
274.94M – 274.94M
-11.1% YoY
|
320.77M
320.77M – 320.77M
+16.7% YoY
|
458.25M
458.25M – 458.25M
+42.9% YoY
|
| SGA |
115.34M
est: 74.61M (+54.6%)
|
121.17M
est: 136.92M (-11.5%)
|
133.20M
est: 135.19M (-1.5%)
|
137.72M
est: 182.89M (-24.7%)
|
224.98M
est: 225.68M (-0.3%)
|
298.86M
est: 298.75M (+0.0%)
|
320.48M
est: 321.90M (-0.4%)
|
291.18M
est: 445.27M (-34.6%)
|
347.70M
est: 544.74M (-36.2%)
|
414.59M
est: 534.47M (-22.4%)
|
504.20M
est: 527.34M (-4.4%)
|
608.20M
est: 501.92M (+21.2%)
|
544.55M
544.55M – 544.55M
+8.5% YoY
|
609.51M
609.51M – 609.51M
+11.9% YoY
|
689.69M
689.69M – 689.69M
+13.2% YoY
|
| EPS |
-0.02
|
0.00
est: 0.02 (-95.0%)
|
0.04
est: 0.02 (+50.9%)
|
0.04
est: 0.03 (+25.1%)
|
0.03
est: 0.03 (-16.5%)
|
0.03
est: 0.04 (-12.0%)
|
0.05
est: 0.04 (+39.2%)
|
0.07
est: 0.08 (-15.1%)
|
0.08
est: 0.10 (-22.5%)
|
0.06
est: 0.08 (-26.0%)
|
0.05
est: 0.07 (-27.4%)
|
0.03
est: 0.07 (-52.8%)
|
0.06
0.06 – 0.06
-11.1% YoY
|
0.07
0.07 – 0.07
+16.7% YoY
|
0.10
0.10 – 0.10
+42.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.38% | 247.3K | 0.59% |
| 2 | Global X - Aging Population ETF AGNG | 0.22% | 187.1K | 0.50% |
| 3 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.05% | 37.1K | 0.74% |
| 4 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.05% | 335.9K | 0.65% |
| 5 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 117.8K | 0.74% |
| 6 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 126.4K | 0.72% |
| 7 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.03% | 184.2K | 0.55% |
| 8 | Avantis Emerging Markets Value ETF AVES | 0.03% | 409.8K | 0.36% |
| 9 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.02% | 62.0K | 0.35% |
| 10 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 23.7K | 0.42% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yuehui Xie | Chairman & Chief Executive Officer | 13M | male |
| Jianxiong Liu | Chief Financial Officer, Executive Vice President, Company Secretary & Executive Director | 13M | male |
| Xingmei Ruan | Chief Compliance Officer | 1M | female |
| Liping Wu | Executive Director | 327.9K | female |
| Xiaoling Feng | Executive Director | 327.9K | female |
| Yu Fang | Executive Director | 327.9K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1302.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
